Human cognition assessment in drug research

Current Pharmaceutical Design

Volumn 12, Issue 20, 2006, Pages 2525-2539

  Riedel, Wim J ^a,b,c   Mehta, Mitul A ^d,e   Unema, Pieter J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Attention; Cognitive psychology; Noradrenergic system; Processing capacity; Schizophrenia; Working memory

Indexed keywords

ADRENALIN; ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; BIPERIDEN; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DEOXYGLUCOSE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; KETAMINE; MECAMYLAMINE; METHYLPHENIDATE; METIROSINE; NORADRENALIN; PHENYLALANINE; SCOPOLAMINE; TRYPTOPHAN; TYROSINE;

ACCURACY; ADRENALIN BLOOD LEVEL; ALZHEIMER DISEASE; ANXIETY DISORDER; APTITUDE TEST; ARTIFICIAL NEURAL NETWORK; ATTENTION; ATTENTION DEFICIT DISORDER; AUDITORY MEMORY; AUTONOMIC NERVOUS SYSTEM FUNCTION; BEHAVIORAL RESEARCH; BRADYCARDIA; BRAIN BLOOD FLOW; BRAIN METABOLISM; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; COGNITION; COMPUTER SIMULATION; CONSTRUCT VALIDITY; CONTENT VALIDITY; DEMENTIA; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG DESIGN; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TARGETING; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FACE VALIDITY; FACTORIAL ANALYSIS; FUNCTIONAL ASSESSMENT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART ARRHYTHMIA; HEART RATE; HEART RATE VARIABILITY; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LONG TERM MEMORY; MATHEMATICAL MODEL; MEMORY; MEMORY CONSOLIDATION; MYDRIASIS; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; NULL HYPOTHESIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; PSYCHOPHARMACOLOGY; QUANTITATIVE ANALYSIS; RATING SCALE; REACTION TIME; RECALL; RECOGNITION; REVIEW; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SENSORIMOTOR FUNCTION; SHORT TERM MEMORY; SPATIAL MEMORY; STANDARDIZATION; STATISTICAL MODEL; TASK PERFORMANCE; TEST RETEST RELIABILITY; THEORETICAL MODEL; VISUAL MEMORY; WORKING MEMORY;

ATTENTION; BEHAVIOR; BIOLOGICAL MARKERS; COGNITION; DATA INTERPRETATION, STATISTICAL; HUMANS; MENTAL PROCESSES; NEUROPSYCHOLOGICAL TESTS; NEUROPSYCHOLOGY; PSYCHOPHARMACOLOGY; REPRODUCIBILITY OF RESULTS; RESEARCH;

EID: 33745742592     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698882     Document Type: Review

References (119)

1. Markowitsch H. Intellectual Functions and the Brain. An Historical Perspective. Seattle: Hogrefe & Huber. 1992.
2. Vermeeren A, Riedel WJ, Van Boxtel MPJ, Paty I, Darwish M, Patat A. Hangover effects of zaleplon and zopiclone on memory, psychomotor performance and actual driving: a comparison with effects of a low dose of alcohol. Sleep 2002; 25: 224-31.
3. Spiegel R. Psychopharmacology: an introduction (3rd ed.). Chichester: John Wiley and Sons. 1995.
4. Skinner BF. Science and Human Behaviour. New York: The Free Press. 1953.
5. Mehta MA, Gumaste D, Montgomery AJ, McTavish SF, Grasby PM. The effects of acute tyrosine and phenylalanine depletion on spatial working memory and planning in healthy volunteers are predicted by changes in striatal dopamine levels. Psychopharmacology (Berl) 2005; 180: 654-63.
6. Salmeron BJ, Stein EA. Pharmacological applications of magnetic resonance imaging. Psychopharmacol Bull 2002; 36: 102-29.
7. Stein EA. fMRI: a new tool for the in vivo localization of drug actions in the brain. J Anal Toxicol 2001; 25: 419-24.
8. Hunt E. What do we need to know about aging? In J Cerella, J Rybash, W Hoyer & ML Commons Eds., Adult Information Processing: Limits on Loss. San Diego: Academic Press Inc. 1993; 587-598.
9. Newell A, Simon H. Human Problem Solving. Englewood Cliffs, NJ: Prentice-Hall. 1972.
10. Ericsson Y, Simon H. Protocol Analysis. Cambridge, MA: MIT Press. 1994.
11. Hobus P. Expertise van huisartsen. Praktijkervaring, kennis en diagnostische hypothesevorming. Maastricht: Rijksuniversiteit Limburg. 1994.
12. Prasangsit P. Newell & Simon: The Theory of Human Problem Solving. Retrieved 15 Dec 2004, 2004, from http://www.cc.gatech.edu/~jimmyd/summaries/newell19-2.html 1999, Mon May 3 03:02:17 EDT 1999.
13. Sanders AF. Drugs, driving and the measurement of human performance. In JF O'Hanlon & JJd Gier Eds., Drugs & Driving. London: Taylor & Francis. 1986; 3-16.
14. O'Hanlon JF, Brookhuis KA, Louwerens JW, Volkerts ER. Performance testing as part of drug registration. In JF O'Hanlon & JJ De Gier Eds., Drugs & Driving. London: Taylor & Francis. 1986; 311-330.
15. Gaillard A. The evaluation of drug effects in laboratory tasks. In I Hindmarch, B Aufdembrinke & H Ott Eds., Psychopharmacology and reaction time. Chichester, England: John Wiley & Sons. 1988; 5-24.
16. Riedel WJ, Hamers HMW, Robbe HWJ, Vermeeren A, O'Hanlon JF. Automated behavioural testing in psychotropic drug research. In LJM Mulder, FJ Maarse, WPB Sjouw & AE Akkerman Eds., Computers in psychology: Applications in education, research and psychodiagnostics. Amsterdam, Netherlands: Swets & Zeitlinger. 1991; 166-170.
17. Wesnes K. Assessing cognitive function in clinical trials: latest developments and future directions. Drug Discov Today 2002; 7: 29-35.
18. Pribram KH, McGuinness D. Arousal, activation, and effort in the control of attention. Psychol Rev 1975; 82: 116-149.
19. Robbins T, Everitt B. Arousal Systems and Attention. In M Gazzaniga Ed., The Cognitive Neurosciences. Cambridge MA (USA): MIT Press. 1995; 703-720.
20. Schmidt RF, Wiesendanger M. Motorische Systeme. In RF Schmidt & G Thews Eds., Physiologie des Menschen. Berlin: Springer. 1987.
21. Lyon M, Robbins TW. The action of central nervous system stimulant drugs: a general theory concerning amphetamine effects. In W Essman & L Valzelli Eds., Current Developments in Psychopharmacology. New York: Spectrum. 1975; 2: 79-163.
22. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychistric phenotypes. Neuropsychopharmacology 2004; 29: 1943-1961.
23. Robbins TW. Arousal Systems and Attentional Processes. Biol Psychol 1997; 45: 57-71.
24. Riedel WJ, Vermeeren A, Van Boxtel MPJ, Vuurman EFPM, Verhey FRI, Jolles J, et al. Mechanisms of Drug-Induced Driving Impairment: A Dimensional Approach. Hum Psychopharmacol 1998; 13: S49-63.
25. Wetherell A. Performance tests. Environ Health Perspect 1996; 2: 247-73.
26. Sanders AF. Towards a model of stress and human performance. Acta Psychologica 1983; 53: 61-97.
27. Frowein HW, Sanders AF. Effects of amphetamine and barbiturate in a serial reaction task under paced and self-paced conditions. Acta Psychologica 1978; 42: 263-276.
28. Warburton DM, Wesnes K. Drugs as research tools in psychology: Cholinergic drugs and information processing. Neuropsychobiology 1984; 11: 121-132.
29. Callaway E. The pharmacology of human information processing. Psychophysiol 1983; 20: 359-371.
30. Callaway E, Halliday R, Naylor H, Yano L, Herzig K. Drugs and human information processing. Neuropsychopharmacology 1994, 10: 9-19.
31. Sawaguchi T, Iba M. Prefrontal cortical representation of visuospatial working memory in monkeys examined by local inactivation with muscimol. J Neurophysiol 2001; 86: 2041-53.
32. Revelle W. Individual differences in personality and motivation; 'non-cognitive' determinants of cognitive performance. In A Baddeley & L Weiskrantz Eds., Attention, Selection, Awareness and Control. Oxford: Clarendon Press. 1993.
33. Cohen JD, Dunbar K, McClelland JL. On the control of automatic processes: a parallel distributed processing account of the Stroop effect. Psychol Rev 1990; 97: 332-61.
34. Mulder G. The concept and measurement of mental effort. In Hockey GRJ, Gaillard AWK, Coles MGH, Eds., Energetics and human information processing. Dordrecht: Martinus Nijhoff. 1986; 175-198.
35. Kahneman D. Attention and effort. Englewood Cliffs, NJ: Prentice Hall. 1973.
36. Norman DA, Bobrow DG. On data-limited and resource-limited processes. Cognitive Psychology 1975; 7: 44-64.
37. Mattay VS, Berman KF, Ostrem JL, Esposito G, Van Horn JD, Bigelow LB, et al. Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. J Neurosci 1996; 16: 4816-4822.
38. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos Transact A Math Phys Eng Sci 2004; 362: 2871-2888.
39. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J. Neurosci 2000; 20: RC65:1-6.
40. Weingartner H, Eckardt M, Molchan S, Sunderland T, Wolkowitz O. Measurement and interpretation of changes in memory in response to drug treatments. Psychopharmacol Bull 1992; 28: 331-340.
41. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994; 5: 266-81.
42. Robbins TW, James M, Owen AM, Sahakian BJ, Lawrence AD, McInnes L, et al. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging.Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc 1998; 4: 474-90.
43. Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 2000; 152: 353-361.
44. Sternberg S. Memory scanning: mental processes revealed by reaction time experiments. Am Scient 1969; 57: 421-457.
45. Sanders AF. Energetics, Stress and Sustained Attention. In AF Sanders Ed., Elements of Human Performance. New Jersey: Lawrence Erlbaum Associates. 1998; 394-451.
46. Parrott AC. Performance tests in human psychopharmacology: I. Test reliability and standardization. Hum Psychopharmacol 1991; 6: 1-9.
47. Parrott AC. Performance tests in human psychopharmacology: II. Content validity, criterion validity, and face validity. Hum Psychopharmacol 1991; 6: 91-98.
48. Parrott AC. Performance tests in human psychopharmacology: III. Construct validity and test interpretation. Hum Psychopharmacol 1991; 6: 197-207.
49. Rosnow RL, Rosenthal R (Eds.). People studying people. Artifact and Ethics in behavioural research. New York, NY: W. H. Freeman & Co. 1997.
50. Green JB, Elder WW, Freed DM. The P1 component of the middle latency auditory evoked potential predicts a practice effect during clinical trials in Alzheimer's disease. Neurology 1995, 45: 962-966.
51. Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol 2002; 1: 473.
52. Stein RA, Strickland TL. A Review of the Neuropsychological Effects of Commonly Used Prescription Medications. Arch Clin Neuropsychol. 1998; 13: 259-284.
53. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189-209.
54. Riedel WJ, Van Praag HM. Avoiding and Managing Anticholinergic Effects of Antidepressants. CNS Drugs 1995; 3: 245-259.
55. King DJ, Henry G. The effect of neuroleptics on cognitive and psychomotor function. A preliminary study in healthy volunteers. Br J Pychiatry 1992; 160: 647-53.
56. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-55.
57. Curran HV. Benzodiazepines, memory and mood: A review. Psychopharmacology 1991; 105:1-8.
58. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004; 18: 297-328.
59. Shamsi Z, Hindmarch I. Sedation and Antihistamines: A Review of Inter-Drug Differences using Proportional Impairment Ratios. Hum Psychopharmacol Clin Exp 2000; 15: 3-30S.
60. Geyer MA, Tamminga CA. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 2004; 174: 1-2
61. Marder SR, Fenton W, Youens K. Schizophrenia, IX: Cognition in schizophrenia - the MATRICS initiative. Am J Psychiatry 2004; 161: 25.
62. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004; 72: 1-3.
63. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72: 29-39.
64. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res 2004; 72: 5-9.
65. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatr 2004; 56: 301-7.
66. Lowe C, Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Neuropsychologia 1998; 36: 915-923.
67. Hockey GRJ. Changes in operator efficiency as a function of environmental stress, fatigue, and cireadian rhythms. In KR Boff, L Kauffman & JP Thomas Eds., Handbook of Perception and Human Performance. New York: Wiley. 1986; 2: 44-49.
68. Biomarkers,. Definitions, Working, Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
69. Kramer AF. Physiological metries of mental workload: a review of recent progress. In DL Damos Ed., Multiple Task Performance. London: Taylor and Francis 1991.
70. Kapur S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatr 2000; 157 514-520.
71. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol 2001; Suppl: 21S-28S.
72. Honey G, Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004; 25: 366-74.
73. Arthurs OJ, Stephenson CM, Rice K, Lupson VC, Spiegelhalter DJ, Boniface SJ, et al. Dopaminergic effects on electrophysiological and functional MRI measures of human cortical stimulus-response power laws. Neuroimage 2004; 21: 540-6.
74. Wilhelm H. Pupillenreaktionen, Pupillenstoerungen. Stuttgart: Kohlhammer 1991.
75. Unema P. Eye movements and mental Effort. Berlin: Technical University. 1995.
76. Van der Molen MW, Bashore TR, Halliday R, Callaway E. Chronopsychophysiology. In RJ Jennings & MG Coles Eds., Handbook of psychophysiology. New York: Wiley & Sons 1991.
77. Luczak H. Psychophysiologische Methoden zur Erfassung psychophysische Beanspruchungs-zustände. In Arbeitspsychologie, Band D/III/1, Enzyklopädie der Psychologie. Göttingen: Hogrefe Verlag 1987.
78. Casali JG, Wierwille WW. On the measurement of pilot perceptual workload: a comparison of assessment techniques addressing sensitivity and intrusion issues. Ergonomics 1984; 27: 1033-50.
79. Gent W. Volumenpulscurven bei Gefühlen und Affecten. Wundt Philosophische Studien 1903; 18: 715-792.
80. Mulder G. The heart of mental effort. Unpublished Dissertation, Univ of Groningen The Netherlands. 1980.
81. Jennings JR. Do cardiovascular changes indicate energetic support of information processing? In. GRJ Hockey, AWK Gaillard & MGH Coles Eds., Energetics and human information processing. Dordrecht: Martinus Nijhoff Publishers. 1986.
82. Aasman J, Mulder G, Mulder LJ. Operator effort and the measurement of heart-rate variability. Special Issue: Cognitive psychophysiology. Hum Fac 1987; 29: 161-170.
83. Mulder LJ. Measurement and analysis methods of heart rate and respiration for use in applied environments. Biol Psychol 1992; 34: 205-36.
84. Egelund N. Spectral analysis of heart rate variability as an indicator of driver fatigue. Ergonomics 1982, 25: 663-72.
85. Frankenhaeuser M. Psychoneuroendocrine approaches to the study of emotion as related to stress and coping. In HE Howe & RA Dienstbier Eds., Nebraska symposium on motivation 1968. Lincoln: Nebraska Press. 1979; 123-161.
86. Lundberg U, Frankenhaeuser M. Psychophysiological reactions to noise as modified by personal control over noise intensity. Biol Psychol 1978; 6: 51-9.
87. Fibiger W, Singer G. Biochemical assessment and differentiation of mental and physical effort. Work and Stress 1989; 9: 237-247.
88. Mason JW. Organization of Psychoendocrine Mechanisms. In NS Greenfield & RA Sternbach Eds., Handbook of Psychophysiology. New York: Holt, Rinehart and Winston. 1972; 3-17.
89. Bassett JR, Marshall PM, Spillane R. The physiological measurement of acute stress (public speaking) in bank employees. Int J Psychophysiol 1987; 5: 265-73.
90. O'Hanlon JF, Swijgman HF, Vermeeren A. Comparison of alpidem, lorazepam and placebo effects in a combined clinical/psychometric study: a new approach for assessing the behavioural costs and benefits of anxiolytic drug therapy. In G Bartholini, M Garreau, PL Morselli & B Zivkovic Eds., Imidazopyridines in anxiety disorders: a novel and therapeutic approach. New York: Raven Press. 1993.
91. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, Van Veggel LMA, Swijgman HF. Anxiolytics' Effects on the Actual Driving Performance of Patients and Healthy Volunteers in a Standardized Test. An Integration of Three Studies. Neuropsychobiology 1995; 31: 81-88.
92. Wesnes K, Simpson P, Kidd A. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. Hum Psychopharmacol 1988; 3: 27-41.
93. Vermeeren A, Jackson JL, Muntjewerff ND, Quint PJ, Harrsison EM, O'Hanlon JF. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology 1995; 118: 1-9.
94. Riedel WJ, Klaassen T, Deutz NEP, Van Someren A, Van Praag HM. Tryptophan Depletion in Normal Volunteers Produces Selective Impairment in Memory Consolidation. Psychopharmacology 1999; 141: 362-369.
95. Rammsayer TH, Rodewald S, Groh D. Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions. Brain Res Cogn Brain Res 2000; 9: 61-71.
96. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20: 106-118.
97. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Paris: Presses Universitaires de France 1964.
98. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, et al. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 2003; 75: 669-74.
99. Schmitt JAJ, Jorissen BL, Dye L, Markus CR, Deutz NEP, Riedel WJ. Memory function in women with premenstrual complaints and the effect of serotonergic stimulation by acute administration of an alpha-lactalbumin protein. J. Psychopharmacol 2005; 19: 375-384.
100. Hogervorst E, Riedel WJ, Kovacs E, Brouns F, Jolles J. Caffeine improves cognitive performance after strenuous physical exercise. Int J Sports Med 1999; 20: 354-361.
101. Wesnes KA, Simpson PM, White L, Pinker S, Jertz G, Murphy M, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann N Y Acad Sci 1991; 640: 268-71.
102. Wezenberg E, Verkes RJ, Sabbe BGC, Ruigt GSF, Hulstijn W. Effects of Biperiden and Rivastigmine on memory and visuospatial processes. Retrieved 16 march, 2005, from http://www.enpmeeting.nl/enp/enp2004/speakers/thursday/Wezenberg.pdf 2004.
103. Newhouse PA, Potter A, Corwin J, Lenox R. Age-Related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behaviour. Neuropsychopharmacology 1994; 10: 93-107.
104. Oken BS, Kishiyama SS, Kaye JA, Howieson DB. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/ antihistaminergic drug and is distinct from deficits in healthy aging. Neurology 1994; 44: 657-62.
105. Duka T, Ott H, Rohloff A, Voet B. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacolqgy 1996; 123: 361-73.
106. Smith A, Brice C, Nash J, Rich N, Nutt DJ. Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol 2003; 17: 283-92.
107. McCann UD, Penetar DM, Shaham Y, Thorne DR, Gillin JC, Sing HC, et al. Sleep deprivation and impaired cognition. Possible role of brain catecholamines. Biol Psychiatry, 1992; 31: 1082-97.
108. Riedel WJ. Cognitive changes after Acute Tryptophan Depletion; What can they tell us? Psychol Med 2004; 34: 3-8.
109. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003; 169: 215-33.
110. Breier A, Davis OR, Buchanan RW. Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioural effects in humans. Psychopharmacology 1991; 104:479-84.
111. Nilsson LG, Backman L, Karlsson T. Priming and cued recall in elderly, alcohol intoxicated and sleep deprived subjects: a case of functionally similar memory deficits. Psychol Med 1989; 19: 423-33.
112. Neave N, Scholey AB, Emmett JR, Moss M, Kennedy DO, Wesnes KA. Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. Appetite 2001; 37: 255-6.
113. Weinachter SN, Blavet N, O'Donnell RA, MacKenzie ET, Rapin JR. Models of hypoxia and cerebral ischemia. Pharmacopsychiatry 1990; 23: 94-7.
114. Fowler B, Hofer K, Lipitkas J. The exhaustive additivity displayed by nitrous oxide has implications for cognitive-energetical theory. Biol Psychol 2000; 52: 161-80.
115. Van Diest I, Stegen K, Van de Woestijne KP, Schippers N, Van den Bergh O. Hyperventilation and attention: effects of hypocapnia on performance in a stroop task. Biol Psychol 2000; 53: 233-52.
116. van Duinen H, Lorist MM, Zijdewind I. The effect of caffeine on cognitive task performance and motor fatigue. Psychopharmacology (Berl) 2005; 180: 539-47.
117. Carreiras MC, Marco JL. Recent approaches to novel anti-Alzheimer therapy. Curr Pharm Des 2004; 10(25): 3167-75.
118. Marcinko L, Read M. Cognitive therapy for schizophrenia: treatment and dissemination. Curr Pharm Des 2004; 10(18): 2269-75.
119. Rose GM, Hopper A, De Vivo M, Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005; 11(26): 3329-34.